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Risk of Death in Heart Disease is Associated With Elevated Urinary
Globotriaosylceramide
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Derek Blankenship, PhD; Xuan Wang, PhD; Paul A. Grayburn, MD; Matthew R. G. Taylor, MD, PhD; Brian D. Lowes, MD, PhD;
Maria Fuller, PhD; Elfrida R. Benjamin, PhD; Lawrence Sweetman, PhD
Background-—Elevated urinary globotriaosylceramide (Gb3) has been considered a hallmark of Fabry disease, an X-linked
lysosomal disorder that is a risk factor for most types of heart disease.
Methods and Results-—We screened 1421 consecutive patients with common forms of heart disease for Fabry disease by
measuring urinary Gb3 in whole urine using tandem mass spectrometry, a-galactosidase A activity in dried blood spots, and we
looked for GLA mutations by parallel sequencing of the whole gene (exons and introns) in pooled genomic DNA samples followed
by Sanger sequencing veriﬁcation. GLA variants were found in 13 patients. In the 1408 patients without GLA mutations, urinary
Gb3 levels were signiﬁcantly higher in heart disease patients compared to 116 apparently healthy controls (median
difference=10.0 ng/mL and P<0.001). Urinary lipid proﬁling showed that levels of 5 other lipids signiﬁcantly distinguished
between urine of patients with Fabry disease (n=7) and heart disease patients with elevated urinary Gb3 (n=6). Sphingomyelin and
Gb3 levels were abnormal in the left ventricular wall of patients with ischemic heart failure. Elevated levels of urinary Gb3 were
independently associated with increased risk of death in the average follow-up of 17 months (hazard ratio=1.59 for increase in Gb3
of 200, 95% CI=1.36 and 1.87, and P<0.0001).
Conclusions-—In heart disease patients who do not have Fabry disease or GLA gene mutations, a higher level of urinary Gb3 is
positively associated with near-term mortality. The elevation of urinary Gb3 and that of other lipids suggests that heart disease is
associated with multiorgan lipid abnormalities.
Clinical Trial Registration-—URL: clinicaltrials.gov. Unique Identiﬁer: NCT01019629. ( J Am Heart Assoc. 2014;3:e000394
doi: 10.1161/JAHA.113.000394)
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A lthough the number of potential cardiovascular biomar-kers continues to grow, most provide only limited added
value to established biomarkers for predicting pathology and
outcomes. This is probably because the newer markers are
not truly mechanistically independent, but rather connected
to pathways already known to be associated with cardiovas-
cular disease (eg, inﬂammation, thrombosis/hemostasis,
cholesterol transport).1 Certain known biomarkers are useful.
For example, the persistent increases in blood levels of
biomarkers such as troponin or natriuretic peptide are known
to have prognostic value in post-myocardial infarction
patients.2 To date, no biomarker has emerged as the best
screening indicator for cardiovascular disease.3
Fabry disease is an X-linked genetic disorder (OMIM
301500). The incidence of the disease has been estimated
to be at 1 in 117 000 live male births,4 however, recent
newborn screening surveys suggest that the incidence may
be as high as 1:3100.5 Its major complications are an
increased risk of stroke, cardiac disease including cardio-
myopathy, atrio-ventricular conduction defects, arrhythmia,
valvular dysfunction, cardiac vascular disease, and progres-
sive renal failure.6 Fabry disease is caused by a deﬁciency of
the lysosomal enzyme a-galactosidase A and accumulation
of the glycosphingolipid globotriaosylceramide (Gb3) in most
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cells and organs, as well as an increase of Gb3 in urine.
7–9
Urinary Gb3 is not primarily in the ﬁltrate, but is mostly in
shed renal tubular cells.9,10 Increased urinary Gb3 is
considered a hallmark of the disease, is considered to be
speciﬁc for Fabry, and is often used in screening for this
disorder.11,12
In a prospective screening study for Fabry disease among
patients with common forms of heart disease, we found that
Gb3 is elevated not only in patients with Fabry disease but
also in the general population of patients with non-Fabry–
related heart disease. We looked for abnormalities in other
urinary lipids in this patient population and investigated their
possible relevance to the heart. We then hypothesized that
elevated Gb3 may be a risk marker in patients with heart
disease and may have prognostic value for assessment of
near-term risk of death.
Materials and Methods
Clinical Study
We screened for Fabry disease in a population of patients
with multiple forms of cardiovascular disease (ClinicalTri-
als.gov Identiﬁer: NCT01019629). These included coronary
artery disease (CAD), conduction or rhythm abnormalities,
nonischemic cardiomyopathy, or valvular dysfunction. The
patients were ambulatory, had to be over 18 years of age and
were seen at a number of institutions in Dallas: Baylor Heart
and Vascular Hospital in Dallas, the Heart Hospital at Baylor
Plano, Soltero Cardiovascular Research Center, and cardiol-
ogy outpatient clinics in Dallas, Texas. More than 95% of
patients who were asked to participate in the study accepted
and gave a written informed consent (1421 patients). The
Institutional Review Board (IRB) of the Baylor Research
Institute provided oversight for the heart disease Gb3 study
while the IRB at the University of Colorado had oversight for
the heart transplant part of the study. In parallel, healthy
control subjects were recruited among friends and relatives
of patients with heart disease admitted to the heart hospitals
or seen in the clinics. Apparently healthy controls used for
comparison of urinary Gb3 levels were subjects recruited to
the study who had no history of any cardiac disease and were
not taking any cardiac related medications. Screening was
performed by measuring urinary Gb3 in randomly collected
samples of whole urine using ultra high pressure chroma-
tography-tandem mass spectrometry (UPLC-MS/MS), mea-
suring a-galactosidase A activity in dried blood spots by ﬂow
injection analysis-tandem mass spectrometry (FIA-MS/MS),
and looking for GLA gene mutations by parallel sequencing of
the whole gene in pooled genomic DNA samples. Conven-
tional Sanger sequencing was used to further analyze
individual samples from selected patient DNA pools. Mortality
(all causes) of a patient was determined by accessing the
Social Security Death Index.
Urinary Gb3 Analysis by Mass Spectrometry
Urinary Gb3 was measured by UPLC-MS/MS. We saw no
effect on Gb3 levels up to 3 freeze/refreeze cycles. None of
the urinary Gb3 measurements were in urine that underwent
more than 2 freeze/refreeze cycles. The analytical method
was based on a published method13 with some modiﬁca-
tions.14 Brieﬂy, 25 lL of C17-Gb3 at a concentration of
50 lg/mL were added to 1 mL of urine dried on a 595 cm
ﬁlter paper square and were extracted with 4 mL of methanol.
Ten microliters were injected into the UPLC-MS/MS system.
Chromatography with a fast methanol/water gradient was
performed using a C8 BEH, 1950 mm, 1.7 lm UPLC column,
at 60°C, with a total run time of 3 minutes, including column
re-equilibration. Gb3 was detected with a Quattro Premier
tandem mass spectrometer, in positive ion mode. Multiple
reaction monitoring (MRM) transitions were: m/z 1060.6?
898.6 for C17-Gb3 and 1046.6?884.6 for C16:0, 1074?
912.6 for C18:0, 1102?940.6 for C20:0, 1128?966.6 for
C22:1, 1130?968.6 for C22:0, 1156?994.6 for C24:1,
1158?996.6 for C24:0, 1174?1012.6 for C24:0(OH) for a
total of 8 Gb3 isoforms. Concentrations of urinary Gb3 were
expressed as ng/mL. We had previously determined that it is
preferable to express urinary Gb3 concentration per urine
volume rather than creatinine concentration.15
a-Galactosidase A Activity Evaluation by Tandem
Mass Spectrometry
The analytical procedure was based on the “Triplex”
method.14 A 3-mm dried blood spot punch was incubated
for 18 hours at 37°C in a single assay buffer with substrate
and internal standard. Fabry internal standard (a-galactosi-
dase A [GLA]-IS) and Fabry substrate were from Drs H. Zhou
and V. De Jesus (CDC, Atlanta, GA, USA).
The samples were processed by a simple liquid-liquid
extraction by using ethyl acetate. The extracts were dried and
resuspended in 80/20 v/v acetonitrile/water with 0.2%
formic acid for injection into the tandem mass spectrometer.
Products and internal standard were monitored by MRM.14
Samples were processed in a 96-well plate and each plate
included 6 blank samples and quality controls in duplicate.
Quality control DBS samples (low, medium, and high) were
obtained from Drs H. Zhou and V. De Jesus at the CDC in
Atlanta. Twenty microliters were injected for ﬂow injection
analysis—tandem mass spectrometry using a Micromass
(Waters) Quattro LC triple quadrupole. The ﬂow rate was
40 lL/min. MRM transitions were m/z 489.3?389.3 for
[GLA]-IS and m/z 483.3?383.3 for GLA product.
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Gb3 Analysis of Heart Tissue by Mass
Spectrometry
Human heart tissue (left ventricular tip, full wall thickness) was
obtained at the time of transplantation from patients with end-
stage heart failure due to ischemic heart disease. Control
samples from subjects without heart failure were obtained
from hearts harvested for transplantation, but unutilized for
noncardiac reasons. Both patients and controls were randomly
selected. Tissue was ﬂash frozen in liquid nitrogen according
to methods we have previously described. The research was
approved by the IRBs at the University of Colorado.16
To perform heart tissue Gb3 quantitation, homogenates
were prepared by adding 16 lL of ice-cold deionized water
per mg of heart tissue. 50:50 acetone:methanol was added to
the homogenate (ratio 20:1), the mixture was vortexed,
rehomogenized, and centrifuged at 10 600g for 10 minutes at
room temperature. A 50 lL aliquot of each supernatant was
transferred to a 13 mL silanized glass tube and prepared for
solid phase extraction (SPE); successive additions of 200 lL
DMSO, 150 lL of 1:20 water (1:1 acetone:methanol), 50 lL
C17-CTH internal standard (from porcine red blood cell [RBC];
Matreya, LLC) at a ﬁnal concentration of 1 lg/mL, and
600 lL of water: methanol (13:87) were brieﬂy vortexed and
loaded onto a pre-conditioned Varian Bond Elut 40 lm,
100 mg C-18 column (Varian Inc). After elution, the column
was washed with 67:23:10 methanol:acetone:water. Gb3 was
eluted from the column with 1 mL of 9:1 acetone:methanol
into silanized glass tubes containing 300 lL of DMSO.
Samples were evaporated to the DMSO layer at 40°C for
10 minutes and vortexed. Ten microliter were injected into a
LC-MS/MS system (LC: Shimadzu Corporation; MS/MS:
4000QTRAP LC/MS/MS, Applied Biosystems) at room tem-
perature. The separation was carried out on a C18 analytical
column (Phenomenex Aqua 3 lm 10093.0 mm, 125A;
Phenomenex) under gradient elution with acetone/metha-
nol/acetonitrile with sodium acetate binary mobile phase
system at a ﬂow rate of 0.5 mL/min. MS/MS analysis was
performed in positive ion mode (ESI+): ionspray voltage of
+5500 V, a source temperature of 400°C, a curtain gas ﬂow
of 20 psi, a Gas1 ﬂow of 60 psi, a Gas2 ﬂow of 40 psi, a de-
clustering potential (DP) in the [+251 to +336] V range, and a
collision energy (CE) in the [+83 to + 93] V range. The
following 12 transitions were monitored: m/z 1046.70?m/z
884.7 for C16:0; m/z 1074.8?m/z 912.8 for C18:0; m/z
1102.8?m/z 940.8 for C20:0; m/z 1128.8?m/z 966.8 for
C22:1; m/z 1130.9?m/z 968.8 for C22:0; m/z 1144.9?m/z
982.8 for C23:0; m/z 1146.9?m/z 984.8 for C22:0(2OH);
m/z 1154.9?m/z 992.8 for C24:2; m/z 1156.9?m/z
994.8 for C24:1; m/z 1158.9?m/z 996.9 for C24:0; m/z
1172.9?m/z 1010.8 for C24:1(2OH); m/z 1174.9?m/z
1012.8 for C24:0(2OH); and m/z 1060.7?m/z 898.6 for the
C17-CTH internal standard. The ratio of the total Gb3 area
counts (sum of 12 isoforms) to that of the internal standard
was used to calculate the concentration of Gb3 in each
sample based on a linear equation ﬁtted with the weighting
factor 1/x2. Total Gb3 measurements were normalized to wet
tissue weight.
Table 1. Summary Statistics by Disease Status, Age, Gender, Urinary Gb3 Levels (ng/mL) and Ethnic Background
Variable
Apparently Healthy Controls (N=116) Cardiac Patients (N=1408)
P ValueN Median (Q1 to Q3) N Median(Q1 to Q3)
Gb3 116 90 (72 to 111) 1406 100 (78 to 140) <0.001
Age, y* 116 44 (33 to 54) 1406 65 (56 to 73) <0.001
N (%) N (%)
Gender
Female 79 (68.1) 494 (35.1) <0.001
Male 37 (31.9) 914 (64.9)
Ethnicity
Hispanic 7 (6.0) 55 (3.9) 0.322
Non-Hispanic 109 (94.0) 1353 (96.1)
Race
Black 6 (5.2) 91 (6.5) 0.021
White/Caucasian 102 (87.9) 1282 (91.2)
Other 8 (6.9) 33 (2.3)
Gb3 indicates globotriaosylceramide.
*Urinary Gb3 was independent of age.
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Table 2. Summary Statistics for 1408 Heart Disease Patients by Death Status
Alive (N=1333) Deceased (N=75) P Value
Demographic
Categorical Variable N (%) N (%)
Gender
Female 473 (35.5) 20 (26.7) 0.152
Male 860 (64.5) 55 (73.3)
Ethnicity
Hispanic 55 (4.1) 0 (0.0) 0.115
Non-Hispanic 1271 (95.9) 75 (100.0)
Race
Black 85 (6.4) 6 (8.0) 0.474
White/Caucasian 1213 (91.3) 69 (92.0)
Other 31 (2.3) 0 (0.0)
Continuous Variable N Mean (SD) N Mean (SD)
Age, y 1331 63.2 (12.7) 75 69.5 (9.1) <0.001
Follow-up, months 1331 17.1 (10.7) 75 9.7 (8.5) <0.001
Gb3, ng/mL 1331 122.3 (87) 75 187.2 (308.8) <0.001
AlphaGAL, mmol/L per hour 1302 6 (3.9) 74 6.2 (5) 0.673
Main Diagnosis N (%) N (%)
CAD 859 (64.5) 59 (78.7) 0.017
Cardiomyopathy 117 (8.8) 11 (14.7) <0.001
Valvular disease 186 (14.0) 12 (16.0) 0.753
Arrhythmia/conduction abn 604 (45.4) 39 (52.0) 0.320
Risk Factors
Continuous Factors N Mean (SD) N Mean (SD)
BMI 1331 29.9 (6.8) 75 28 (5.8) 0.018
Ejection fraction, % 917 49.4 (15.1) 59 39.5 (17.7) <0.001
eGFR*, mL/min per 1.73 m2 1288 69.3 (25.5) 74 53.2 (25.3) <0.001
HDL, mg/dL 1079 45.4 (17.9) 57 38.6 (12.5) 0.005
LDL, mg/dL 1084 96.5 (35.5) 58 92 (44.4) 0.354
Categorical Factors N (%) N (%)
Hypertension† 1046 (78.6) 66 (88.0) 0.071
Proteinuria 130 (9.8) 4 (5.3) 0.281
Diabetes 191 (14.4) 17 (22.7) 0.073
Onset < age 40 67 (5.0) 1 (1.3) 0.259
Medications N (%) N (%)
ACE 536 (40.3) 31 (41.3) 0.955
ARB 261 (19.6) 20 (26.7) 0.178
Analgesic 842 (63.4) 50 (66.7) 0.180
Antihyperlidemic 947 (71.3) 55 (73.3) 0.806
Antiplatelet agent 412 (31.0) 28 (37.3) 0.307
b-Blocker 444 (33.4) 23 (30.7) 0.716
Anticoagulant 330 (24.8) 28 (37.3) 0.022
Continued
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Lipid Proﬁling of Urine and Heart Tissue
Pieces of heart tissue were thawed and homogenized in 1 mL
0.5 mol/L NaCl, 20 mmol/L Tris, pH 7, using a Microson
Ultrasonic Cell Disruptor, and total protein was determined by
the Lowry method.17 Lipids were extracted from 0.1 mg of
protein by the Folch method18 and from 1.5 mL of urine by
the Bligh and Dyer19 method with the inclusion of 400 pmol
of the following internal standards: bis (monoacylglycero)
phosphate (BMP) 14:0/14:0, ceramide 18:1/17:0, dihexosyl-
ceramide (DHC) 18:1/16:0 (d3), monohexosylceramide
(MHC) 18:1/16:0 (d3), phosphatidylethanolamine (PE) 17:0/
17:0, phosphatidylglycerol (PG) 14:0/14:0, phosphatidyinos-
itol (PI) 16:0/16:0, phosphatidylserine (PS) 17:0/17:0, cho-
lesteryl heptadecanoate 17:0 and 100 pmol of lysoPC 13:0
and lyso PE 14:0. Dried lipid extracts were resuspended in
0.2 mL of methanol containing 10 mmol/L NH4COOH and
20 lL were injected onto a 3 lm Alltima C18 column
(5092.1 mm) at a ﬂow rate of 0.2 lL/min in 70% mobile
phase A (30% tetrahydrofuran/20%CH3OH/10%H2O in
5 mmol/L NH4COOH). This was then linearly converted to
100% mobile phase B (70% tetrahydrofuran/20%CH3OH/10%
H2O in 5 mmol/L NH4COOH) over 7 minutes and maintained
for 3 minutes prior to the next injection. A divert valve was
used for the ﬁrst 1.6 minutes. Following chromatography,
individual species of ceramide, MHC, DHC, SM, PC, PI, PE, PS
and cholesterol were quantiﬁed by ESI-MS/MS as
described,20 and BMP and PG as described.21 LysoPC and
lysoPE were quantiﬁed in positive and negative ion in the
MRM mode, respectively. For lysoPC the ion spray voltage
was +5500, source temperature 200°C, curtain gas, gas 1
and 2 ﬂow 10 psi, DP 106, CE 37, and 16 isoforms were
measured using the m/z product ion of 184 corresponding to
the phosphocholine head group. For lysoPE the ion spray
voltage was 4500, source temperature 200°C, curtain gas
ﬂow 10 psi, gas 1 ﬂow 16 psi and gas 2 ﬂow 10 psi, DP 70,
CE 33, and 12 isoforms were measured using the m/z
product ion of 196 corresponding to the dilyso-H2O. Concen-
trations of individual species were calculated by relating the
AUC to that for the corresponding internal standard. The total
amount of each lipid was determined by summing each of the
isoforms. A similar method was used for lipid proﬁling in
plasma.
Determination of Urine Pellet Size
For each sample, 1.5 mL of thawed frozen urine was aliquoted
into an Eppendorf vial in duplicate. The specimens were
centrifuged at low speed (1000g) at 4°C for 10 minutes in
order to precipitate salts and inorganic matter. The superna-
tant was transferred into a second preweighed vial. The
samples were spun at maximum speed (13 500 rpm) for
30 minutes. The supernatant was removed and discarded.
The pellet was dried overnight in a rotary evaporator. The vial
containing the dry residue was weighed again and the weight
of the dry residue was calculated.
Statistical Methods
Comparison of urinary Gb3 levels between cardiac
patients and controls
The difference in urinary Gb3 levels between cardiac patients
and apparently healthy controls was assessed. All subjects
were recruited to the study between March 31, 2010 and
February 3, 2012. Summary statistics are presented by
disease status in Tables 1 and 2. Medians with ﬁrst and third
quartiles and frequencies with percentages are given for
continuous and categorical variables, respectively. Due to Gb3
being skewed, a Wilcoxon test was used to assess the
difference between groups. Furthermore, age, gender, ethnic-
ity, and race were evaluated as confounders. A variance
component model on log (base 10) transformed values of Gb3
was used to adjust for the possible confounders and account
for the difference in variance between the 2 groups.
Table 2. Continued
Alive (N=1333) Deceased (N=75) P Value
Calcium channel block 222 (16.7) 13 (17.3) 0.874
Cardiac glycoside 96 (7.2) 14 (18.7) <0.001
Antiarrhythmics 215 (16.2) 22 (29.3) 0.005
Vasodilator 196 (14.7) 11 (14.7) >0.999
Diuretics 280 (21.1) 35 (46.7) <0.001
Potassium replacement 197 (14.8) 24 (32.0) <0.001
ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CKD-EPI, chronic kidney disease epidemiology
collaboration; eGFR, estimated glomerular ﬁltration rate; GAL, galactosidase; Gb3, globotriaosylceramide; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Using CKD-EPI formula.40
†Whether history of hypertension or current diagnosis.
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Urinary Gb3 levels in patients with heart disease
Summary statistics of patients with heart disease are
presented by death status in Table 2. Means with standard
deviations and frequencies with percentages are given for
continuous and categorical variables, respectively. A Cox
proportional-hazards model was implemented to assess the
relationship between Gb3 and death. The number of deaths
(75) limited the number of variables to include in the model.
Therefore, inverse probability weights (IPWs) were used to
standardize the populations with differing Gb3 values. The
demographic, diagnosis, risk factor, and medication variables
listed in Table 2 were included in the standardization. Deciles
of Gb3 were calculated to determine the standardization
categories. The deciles remained separate if the proportion
of deceased varied and collapsed otherwise. The ﬁnal
categories were Gb3 values ≤63 ng/mL (calculated ﬁrst
decile), 63 to 211 ng/mL, and > 211 (calculated ninth
decile). Gb3 was assessed as a continuous variable on its
original scale in the model with the hazard ratio (HR) being
reported in clinically relevant incremental units of 200.
Values of 100, 500, and 1000 ng/mL were chosen to display
the survival function. The proportional hazards assumption of
the Cox model was assessed using the stratiﬁed analysis
method.22 Missing data were imputed using the expectation-
maximization algorithm.
Figure 1. Globotriaosylceramide (Gb3) value of apparently healthy controls, cardiac cases, and all subjects.
DOI: 10.1161/JAHA.113.000394 Journal of the American Heart Association 6
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Urinary lipid proﬁling comparison in patients with heart
disease, Fabry disease, and controls
In order to ascertain that patients with heart disease and high
urinary Gb3 have a different lipid pattern from Fabry disease
patients, we applied principal component analysis (PCA).
PCA23 is a multivariate dimension reduction procedure that
linearly converts multiple correlated variables (here lipids and
isoforms) into a set of linearly uncorrelated variables called
principal components, among which the ﬁrst principal com-
ponent accounts for the largest variability, and each suc-
ceeding component accounts for the highest variance
possible under the constraint that it be orthogonal to (ie,
uncorrelated with) the preceding components. PCA was used
to supply a lower-dimensional picture of the data and display
3-dimensional (3D) scatterplots with axes being the top 3
principal components.
Given that the lipid isoform variables were highly
skewed, a log (base 10) transformation was applied prior
to principal components. PCA was implemented on the
correlation matrix, which is more robust to skewed
distributions. Eigenvectors and eigenvalues of the correla-
tion matrix were calculated, for which the eigenvector
Figure 2. Log 10 globotriaosylceramide (Gb3) value of apparently healthy controls, cardiac cases, and all
subjects.
DOI: 10.1161/JAHA.113.000394 Journal of the American Heart Association 7
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associated with the largest eigenvalue is the ﬁrst principal
component, and the second largest eigenvalue’s corre-
sponding eigenvector is the second principal component,
etc.
Normal elliptical contour was employed to estimate the
center and radius of the population that a group of samples
comes from. If two 90% coverage contours are separated from
each other in a 3D scatterplot, there is likely to be a distinction
between the corresponding populations. This type of explor-
atory analysis result positively indicates good power for further
statistical inference to discriminate these 2 populations.
Data that were log transformed prior to the ﬁrst PCA were
applied on the correlation matrixes of all lipid isoforms. The
lipid groups that showed a separation pattern between Fabry
and high Gb3 groups using 90% coverage normal contours
ellipsoids were pooled for the second PCA. In order to
evaluate individual isoforms and the top 3 principal compo-
nents for their ability to separate the urinary lipid proﬁle of
Fabry disease patients from that of heart disease patients
with high Gb3, receiver-operating characteristic (ROC) curves
were plotted. To quantify the differential expression of each
isoform between the Fabry group and the group of heart
disease patients with elevated urine Gb3, 2 independent
sample t-tests and Wilcoxon tests were applied on all the
isoforms simultaneously, and false discovery rate (FDR)
multiple comparison corrections were imposed on P values
returned by these 2 tests.24
Results
Patient Population
A total of 1421 consecutive patients were recruited. Thirteen
patients were excluded because of detected variations in the
GLA gene (Table S1). The patients’ characteristics are further
described in Table 1.
Urinary Gb3 is Elevated in Patients With Heart
Disease
There was a statistically signiﬁcant difference in median Gb3
between heart disease patients (Gb3=100) and apparently
healthy controls (Gb3=90, difference=10, and P<0.001). This
difference remained with log-transformed (base 10) (data
difference=0.09, 95% conﬁdence intervals=0.05 and 0.12, and
P<0.0001). The distribution of urinary Gb3 before and after log
transformation in the overall population, cases, and controls is
shown in Figures 1 and 2, respectively. Themodel included age,
gender, ethnicity, and race as possible confounders and they
were not statistically signiﬁcant when included in the model
(Table 3). Moreover, the estimates for the difference between
cases and controls did not show a meaningful change with and
without these variables being included in the model, indicating
they are not confounders in this analysis (minimum and
maximum difference=0.05 and 0.11 on log [base 10] scale,
respectively). Urinary Gb3 levels in apparently healthy controls
were independent of age.
Levels of Other Lipids Are Abnormal in the Urine
of Patients With Heart Disease
In order to investigate whether other lipids besides Gb3 are
elevated in the urine of patients with heart disease, we
performed lipid proﬁling on randomly collected whole urine
and plasma samples on a total of 23 representative samples
of urine belonging to patients with heart disease and elevated
(478 to 886 ng/mL; n=6) or low (55 to 72 ng/mL; n=5) Gb3,
patients with Fabry disease (351 to 9344 ng/mL; n=7) and
apparently healthy controls (57 to 105 ng/mL; n=5). The
upper limit of normal (99th percentile) urinary Gb3 was
200 ng/mL (Table S2).
PCA showed that the isoforms of MHC PC, SM, PS and PE
produced the separation using 90% contours between Fabry
Table 3. Multiple Regression of Log (10) Gb3 on Group, Gender, Race, and Age
Effect Level Estimate Standard Error Num df Den df F Value Pr>F
Group 1 1517 21.65 <0.0001
Control 1.9948 0.0954
Cardiac 2.0823 0.0966
Gender Female 0.0061 0.0115 1 1517 0.28 0.5966
Race (reference group=other) 3 1517 0.44 0.7275
African American 0.0037 0.0944
Asian/Pacific 0.0054 0.0980
Caucasian 0.0178 0.0919
Age 0.0005 0.00043 1 1517 1.37 0.2428
Gb3 indicates globotriaosylceramide.
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disease and heart disease with high urinary Gb3 (Figure 3).
These isoforms were pooled together for PCA analysis and
the 3D contour plots are shown in Figure 3. The ﬁrst Eigen
vector has all its coefﬁcients nonnegative and accounts for
90.6% of the variation. The coefﬁcients of the top 3 principal
components are listed in Table 4. ROC was assessed by AUC
on the top 3 principal components and each lipid isoform is
shown (Table 5). The ﬁrst principal component has an AUC
Figure 3. 3D scatter plot and 90% coverage contour ellipsoids of Fabry and high globotriaosylcera-
mide (Gb3) heart disease patients in spaces spanned by top 3 principal components of (A) MHC, (B) PC,
(C) SM, (D) PS, and (E) PE isoforms. Red dots represent heart disease patients with elevated urinary
Gb3 and green dots patients with Fabry disease. MHC indicates monohexosylceramide; PC,
phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine; SM, sphingomyelin.
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of 1—a perfect separation between the Fabry and high Gb3
groups. Some isoforms also had an AUC of 1 (Table 5).
However, due to the limited sample size, we cannot assess
whether the ﬁrst principal component is better than other
individual isoforms in terms of discriminating between urine
from Fabry patients and that of patients with heart disease
and elevated Gb3.
Multiple comparisons for lipid group summation values and
individual isoforms conﬁrmed that urinary MHC, SM, and PE
were signiﬁcantly different between patients with Fabry
disease and those with heart disease and elevated urinary
Gb3 levels (Table 6). No signiﬁcant differences in lipid proﬁling
were found in plasma from these 2 patient groups (data not
shown).
Table 4. Eigen Value and Eigenvectors on the Top 3 Principal Components
Prin1 Prin2 Prin3
Eigen value 29.00 1.35 0.61
Percent of variation 90.6% 4.2% 1.9%
Eigen vector
GC.C18.1.16.0 0.16878 0.22969 0.34193
GC.C18.1.20.0 0.15490 0.37029 0.40592
GC.C18.1.22.0 0.16710 0.29992 0.32164
GC.C18.1.24.0 0.17468 0.16814 0.33222
PC.C32.0 0.18357 0.00830 0.04633
PC.C32.1 0.18296 0.06891 0.02844
PC.C34.1 0.18366 0.04696 0.01634
PC.C34.2 0.17742 0.01040 0.07155
PC.C36.2 0.17950 0.13986 0.00732
PC.C36.4 0.17582 0.01796 0.10695
PC.C38.4 0.17449 0.08411 0.18098
SM.C18.0.20.0 0.18358 0.05705 0.01530
SM.C18.1.16.0 0.18495 0.05186 0.03634
SM.C18.1.16.1 0.17442 0.16272 0.26107
SM.C18.1.18.0 0.18332 0.08620 0.05964
SM.C18.1.18.1 0.17851 0.09876 0.22643
SM.C18.1.22.0 0.17894 0.14567 0.01782
SM.C18.1.24.0 0.18120 0.12693 0.02211
SM.C18.1.24.1 0.17899 0.17291 0.17461
PS.C18.0.18.2 0.18305 0.01671 0.02929
PS.C18.0.20.4 0.17774 0.10889 0.17537
PS.C18.1.18.0 0.18076 0.06609 0.11805
PS.C18.1.18.1 0.18141 0.09424 0.04303
PE.C16.0.22.4 0.17982 0.07114 0.20636
PE.C18.0.18.2 0.18062 0.09980 0.06485
PE.C18.0.20.4 0.18165 0.05554 0.17645
PE.C18.1.16.0 0.16224 0.36519 0.23054
PE.C18.1.16.1 0.15487 0.42350 0.06496
PE.C18.1.18.0 0.17857 0.20499 0.11338
PE.C18.1.18.1 0.16484 0.35987 0.17578
PE.C18.1.18.2 0.18026 0.07402 0.11517
PE.C18.1.20.4 0.17869 0.08820 0.23740
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Conﬁrmation of Sphingolipid Abnormalities in
Heart Disease Patients
In order to verify our initial lipid proﬁling ﬁndings described
above we studied urinary MHC, SM, and lactosylceramide (LC)
in 8 heart disease patients (Table S2) with elevated urinary
Gb3 randomly selected to represent the full spectrum of Gb3
values, and 6 randomly selected patients from each of the
following: heart disease with normal urine Gb3 and patients
with overt Fabry disease. We conﬁrmed that MHC levels
separated Fabry patients from the heart disease high Gb3
group (Figure 4). Importantly, expression of lipid levels per
unit of volume or per mg creatinine gave consistent results.
Urinary Gb3 Levels Are Independent of the Size of
the Membrane Pellet
In order to determine whether the variation of urinary Gb3 and
other lipids in patients with heart disease reﬂects the amount
of sloughed cellular debris rather than membrane lipid
composition, we measured the size of the pellet in previously
frozen urine samples of 22 patients with heart disease and 6
patients with Fabry disease (Table S2). Urine Gb3 in those
samples ranged from undetectable to 478 ng/mL. There was
no signiﬁcant correlation between the size of the pellet and
the Gb3 concentration in the urine of patients with heart
disease only (P=0.15) and when samples from patients with
Fabry disease were included (P=0.25).
Lipid Abnormalities in Failing Ischemic Heart
In order to determine whether lipid abnormalities seen in urine
reﬂect an abnormal lipid proﬁle in the heart itself, we performed
lipid proﬁling on samples of the left ventricle of 20 patients with
end-stage ischemic heart failure (Table S3).16 Gb3 levels were
signiﬁcantly decreased in these hearts compared to 20 controls
(Figure 5A) while sphingomyelin levels were signiﬁcantly higher
compared to controls (Figure 5B).
Gb3 Levels Are Signiﬁcantly Associated With the
Risk of Near-Term Death
Of the 1408 patients with cardiovascular disease, 75 died
during the follow-up period (Table 2). The total follow-up time,
average follow-up time, and average time to death was 36, 17,
and 10 months, respectively. In order to adjust the analysis
for demographic, clinical, and medication variables listed in
Table 2, a Cox proportional hazard analysis was used. In this
analysis there was a signiﬁcant association between urinary
Gb3 levels and risk of death (HR=1.59 for increase in Gb3 of
200, 95% conﬁdence intervals=1.36 and 1.87, and
P<0.0001). The rate of death increases by 60% for every
increase of 200 units of urinary Gb3. Based on this survival
analysis, the risk estimates for death over time are presented
in Figure 6 using urine Gb3 values of 100, 500, and 1000 ng/
mL. The unadjusted HR (without IPW) produced similar results
(HR=1.52 for increase in Gb3 of 200, 95% conﬁdence
Table 5. AUC for Each Isoform and the Top 3 Principal





































AUC indicates area under the curve; ROC, receiver-operating characteristic.
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intervals=1.30 and 1.77, and P<0.0001). Furthermore, the
robustness of the results was assessed by analyzing 120
different models in which Gb3 was adjusted for each
demographic, diagnosis, risk factor, and medication variable
individually, with and without the IPWs, and with and without
outlier removed. The mean HR from these analyses was 1.49
and ranged from 1.27 to 1.77.
Discussion
In this study we found that glycosphingolipid Gb3 levels in urine
are elevated in some patients with common heart disease who
do not have GLA gene mutations (Fabry disease). The highest
urinary Gb3 levels in patients with heart disease were in the
range seen in themost severe forms of Fabry disease (Table S2).
Furthermore, increasing urinary Gb3 concentrations were
signiﬁcantly associated with increased risk of death in the
subsequent mean follow-up of 17 months. This result was seen
even after adjusting for the type of primary cardiac diagnosis,
medications, and other known risk factors and confounding
factors, suggesting that elevated urinary Gb3 is associated with
relatively near-term death in patients with heart disease.
Gb3 in urine is primarily found in sloughed debris of renal
tissue, mostly renal tubular cells.9,10,25 Because lipid proﬁling
showed that elevation of urinary Gb3 in patients with heart
disease was associated with other lipid abnormalities, it likely
reﬂects abnormal lipid composition of renal cell membranes.
We found support for this hypothesis in the abnormal lipid
proﬁles seen in cardiac tissue from patients with end-stage
ischemic cardiomyopathy and in the fact that the urinary Gb3
elevation was independent of the size of the pellet. Although
urinary lipid proﬁling in patients with common heart disease
has not been previously published, our results in urine of
patients with Fabry disease were similar to previously
published data.26 Glycosphingolipids have been suspected
of being involved in heart disease. Sphingomyelin and
ceramide have been isolated from atherosclerotic plaques in
both humans and animals.27,28 Lowering several sphingolipids
(including sphingomyelin, ceramide, sphingosine-1-phosphate,
and glycosphingolipids) inhibits and even induces regression
of atherosclerotic plaques in animal studies.29 It is thought
that higher levels of sphingolipids are the result of increased
amounts of substrates such as triglycerides.27,28,30 Elevation
of enzymes that catalyze the synthesis of sphingolipids has
been found in samples of the right atrial appendage obtained
from patients at the time of coronary bypass surgery.30
However, to our knowledge, a comprehensive measurement
of lipid levels in the heart of patients with heart disease has
not been published.
Early studies suggested that elevated plasma sphingomy-
elin is associated with a higher rate of complications from
CAD, but recent evidence has not conﬁrmed those ﬁndings.31
Table 6. P Value of Top 3 Principal Components, Individual
Isoform, and Lipid Group Summation Value in MHC, PC, SM,















































MHC indicates monohexosylceramide; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PS, phosphatidylserine; ROC, receiver-operating
characteristic; SM, sphingomyelin.
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Current evidence suggests that glycosphingomyelins such as
the sphingomyelin in atherosclerotic plaques are synthesized
in the atherosclerotic plaques rather than taken up from the
plasma. Since many of the lipids in urine are derived from
sloughed kidney cells, perhaps it is not surprising that the
levels of sphingolipids in urine more closely reﬂect abnormal-
ities in different organs. Furthermore, sphingolipids such as
ceramide, sphingosine, sphingosine-1-phosphate, and lacto-
sylceramide are known to have biological cell signaling
effects, and are involved in pathophysiological processes in
endothelial cells, smooth muscle cells, myocytes, platelets,
and leukocytes.32 In our study, the type of primary cardiac
diagnosis did not signiﬁcantly affect the association of urinary
Gb3 level with the likelihood of death. This suggests that the
lipid abnormalities we identiﬁed in patients with heart disease
represent a systemic lipid aberration that contributes to the
poor prognosis in general by a yet unknown mechanism. We
cannot at present fully explain how urinary Gb3 levels could
predict outcomes for a group of diseases as heterogeneous as
CAD, valvular heart disease, and nonischemic cardiomyopa-
thy. However, these complications frequently coexist in
patients and are thought to have common mechanisms.
For example, atherosclerotic vascular disease increases the
risk of atrial ﬁbrillation and the latter is a major risk factor for
vascular disease. CAD and atrial ﬁbrillation share a number of
risk factors (eg, increasing age, obesity, diabetes, heart failure,
and hypertension), and these complications often coexist33,34
and are associated with most cardiac disorders.35 Remodeling
of ion channels in patients with coronary heart disease and
other heart ailments causes conduction defects possibly due to
sphingolipid abnormalities of lipid rafts.34,36 Unlike existing risk
markers in heart disease that are expressed or released by
cardiovascular tissue in response tomechanical or pathological
stress,37 the Gb3 and other lipid abnormalities we identiﬁed
here may indicate risk via a different mechanism.
Figure 4. 3D 90% contour plots of MHC expressed as per unit of urine volume (A) or per mg of creatinine
(B) of Fabry and high globotriaosylceramide (Gb3) heart disease patients. Red dots represent heart disease
patients with elevated urinary Gb3 and green dots patients with Fabry disease.
Figure 5. Globotriaosylceramide (Gb3) and sphingomyelin (SM)
levels in the left ventricle of failing ischemic hearts. A, Heart Gb3
levels in control vs coronary artery disease (CAD). N=20 per group. B,
Heart SM levels in control vs CAD. N=10 per group. In both panels,
*P<0.05, ***P<0.001 by Welch’s t-test.
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There were several limitations to the study. Although the
sample size was adequate, there were a relatively small number
of deaths. This limited the number of variables we could
simultaneously control for in the Cox proportional hazards
model. Therefore, IPWs were used in the analysis. Despite this
limitation, the results were robust given the fact that a positive
association remained in all 120 models which varied the
variables included in the model (ie, the use of IPW and outlier
removal). The healthy control population of 116 is relatively
small and is younger than the population of patients with heart
disease. This is due to the difﬁculty of ﬁnding completely
healthy subjects of an older age. These differences probably
had no inﬂuence on the results since we included Gb3, age, and
gender in the statistical models. We used the Social Security
Death Index to identify the patients who had died. Although it is
possible that this index is not complete and that the number of
deaths is actually higher, we supplemented our ﬁndings with
obituaries and medical records. This database did not allow us
to ascertain whether the patient died from heart disease or
from another cause. However, the yearly death rate in our study
of about 1.7% was similar to the cumulative all causes mortality
rate found in the Dallas Heart Study.38 Our ﬁndings need to be
conﬁrmed by a study in another population with heart disease.
In addition, since we sampled urine only once per patient in our
study, it is possible that repeated sampling of Gb3 in
combination with the measurement of other lipids would
improve the predictive value of urinary Gb3 levels. Neverthe-
less, the data presented here provide proof of concept for a
potentially new class of risk markers, and predicts future
outcome beyond standard risk factors in cardiovascular
disease.39 An understanding of the mechanisms involved in
the abnormal lipid levels in the urine and in organs will likely
yield novel therapeutic interventions for heart disease.
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   X	   X	  
3.55	  
2208/
4	   5'UTR-­‐30G>A	   M	   56	   	  	   X	   X	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   X	   X	   X	  
7.48	   1261	  
IVS6-­‐22C>T,	  IVS4-­‐16A>G,IVS2+990C>A,5'UTR-­‐
10C>T,	  IVS2-­‐77delC,	  IVS1-­‐518C>T	  
M	   57	   	  	   X	   X	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   X	  
6.86	   289	   IVS2+590C>T	   M	   59	   X	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
5.96	   274	   IVS1-­‐1238G>A	   M	   62	   X	   X	   X	   	  	   X	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   X	   X	  
3.34	   119	   D83N	   F	   71	   X	   	  	   	  	   X	   X	   	  	   	  	   	  	   	  	   X	   	  	   	  	   	  	   X	  
10.02	   96/23	   D313Y(het)	   F	   49	   	  	   X	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   X	   	  	   X	   X	  
3.34	  
368/1
92	   IVS0-­‐12G>A	  IVS4+68A>G	  IVS6-­‐22C>T	  (hemi)	   M	   59	   	  	   X	   X	   	  	   X	   	  	   	  	   X	   X	   	  	   X	   	  	   X	   X	  
3.47	   83	   R118C	   F	   35	   X	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  




IVS0-­‐10C>T	  IVS2-­‐81-­‐-­‐77delCAGCC	  IVS4-­‐16A>G	  
IVS6-­‐22C>T	  (hemi)	   F	   60	   	  	   X	   X	   	  	   	  	   X	   X	   X	   X	   X	   	  	   	  	   X	   X	  
3.27	   216	  
IVS0-­‐10C>T	  IVS2-­‐81-­‐-­‐77delCAGCC	  IVS4-­‐
16A>GIVS6-­‐22C>T	  (hemi)	   M	   58	   	  	   X	   	  	   X	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   X	   	  	  
Gb3:	  200	  ng/mL	  	  99%ile	  
	  α-­‐galactosidase	  A	  activity:	  normal	  >	  2	  umoles/L	  /Hr	  MI:	  myocardial	  infarction;	  Valve:	  valvular	  disease;	  ICM:	  Insertable	  Cardiac	  Monitor;	  HCM:	  hypertrophic	  cardiomyopathy;	  CVA:	  cerebrovascular	  accident;	  DM:	  diabetes	  mellitus;	  COPD:	  chronic	  obstructive	  pulmonary	  disease;	  HTN:	  arterial	  hypertension;	  HLP:	  Hyperlipidemia	  
	   	  
Supplementary	  Table	  2.	  Clinical	  data	  on	  subjects	  used	  for	  urinary	  lipid	  profiling.	  
  
Gb3 levels 
    
  
Urine cards 
    
 



















Cardiac Controls 60 F 34 HIV+ 
 Cardiac Controls 65 M 48 None 
 Cardiac Controls 105 M 44 Hx Bladder Cancer 
Cardiac Controls 74 F 63 HTN  
 Cardiac Controls 57 F 58 HTN  
 Elevated Cardiac Patient 496 M 46 CAD 
 Elevated Cardiac Patient 788 M 66 CAD 
 Elevated Cardiac Patient 584 F 48 CAD  
 Elevated Cardiac Patient 886 F 58 Arrhythmia 
 Elevated Cardiac Patient 478 F 39 CAD 
 Elevated Cardiac Patient 478 M 56 CAD 
 Not elevated Cardiac 71 F 45 CAD 
 Not elevated Cardiac 63 M 54 CAD 
 Not elevated Cardiac 72 M 55 CAD 
 Not elevated Cardiac 64 M 56 CAD  
 Not elevated Cardiac 57 M 56 CAD 
 Fabry  patient 351 M 53   
 Fabry  patient 2696 M 49 
  Fabry  patient 3162 M 29 
  Fabry  patient 2073 M 40 
  Fabry  patient 9344 M 55 
    
       
















  Gb3 Whole Urine ng/mL     
  low Gb3 8 F 71 CAD  
 low Gb3 13 F 55 Arrhythmia 
 low Gb3 14 M 75 CAD 
 low Gb3 14 F 60 Arrhythmia 
 low Gb3 15 M 69 CAD 
 low Gb3 33 M 57 Valvular disease 
Fabry VH M NA 
  Fabry VH M NA 
  Fabry VH M NA 
  Fabry VH M NA 
  Fabry VH M NA 
  Fabry VH M NA 
  
High Gb3 11 M 49 CAD 
 High Gb3 478 F 69 Arrhythmia 
 High Gb3 298 M 77 CAD  
 High Gb3 323 M 46 CAD 
 High Gb3 255 F 49 CAD 
 High Gb3 484 M 66 CAD  
 High Gb3 254 F 62 CAD  
 High Gb3 213 F 69 CAD Arrhythmia Valve 
* GLA Variant 4 M 56 CAD 
 * GLA Variant 23 F 49 CAD 
 * GLA Variant 0 F 71 Arrhythmia HCM 
* GLA Variant 146 F 60 CAD  
 * GLA Variant 49 M 58 CAD 
 * GLA Variant 192 M 59 CAD  
















Fabry 1452 M 40 
  Fabry 2696 M 49 
  Fabry 4539 M 29 
  Fabry VH M 48 
  Fabry 2234 M 55 














478 F 69 CAD 
 298 M 77 CAD  
 284 M 64 CAD 
 264 F 85 CAD  
 255 F 49 CAD 
 254 M 62 CAD  
 247 M 43 CAD   
 244 M 51 HCM 
 237 F 78 CAD 
 213 F 69 CAD   
 204 M 86 Valvular disease 
195 F 67 CAD 
 192 M 59 CAD  
 191 M 65 CAD  
 183 M 56 Valvular disease 
170 M 87 CAD Arrhythmia 
168 M 72 CAD  
 159 F 54 CAD 
 158 F 20 Arrhythmia 
 151 M 58 Arrhythmia 
 
149 F 54 Arrhythmia 
 148 M 41 CAD Valve  
 95 M 53 Arrhythmia 
 90 M 64 Arrhythmia 
 90 M 76 Arrhythmia 
 76 F 43 Valvular disease 
62 M 65 Arrhythmia 
 61 M 62 CAD  
 47 F 72 CAD 
 38 M 62 CAD 
 21 M 47 CAD 
 21 M 64 CAD 
 21 F 54 CAD  
 0 M 64 CAD  
 0 F 77 CAD   
 
 
0 M 69 CAD 
 
       
 
H High: above upper limit of normal, less that 2X the upper limit of normal 
  
 
VH Very High: 5 times above the upper limit of normal  or higher 
  
  
Upper limit of normal as 99 % ile is 200 ng/mL 
    
  
CAD: Coronary Artery Disease 
   
  
HCM: Hypertrophic Cardiomyopathy 
   	   	  







Race Gender Type heart Patient history Cause of death Meds (short list) 
CASE 51 Native American Male CAD/ISCH 
ischemic cardiomyopathy, severe aortic 
insufficiency, congestive heart failure, coronary 
artery disease (diagnosed summer of 2005), anterior 
MI in 7/2005 with stent to proximal LAD, ventricular 
tachycardia, brain tumor, craniotomy with residual 
left-sided 
 
As of 3/31/6:  Aspirin 81 mg every day, 
digoxin 0.125 mg every day, Zocor 20 
mg every 
day, hydralazine 50 mg t.i.d., Isordil 20 
mg t.i.d., spironolactone 25 mg 
every day (suppose to take b.i.d.), 
Lasix 80 mg b.i.d., ICD without any 
discharges, Cozaar 25 m 
CASE 66 White Male CAD/ISCH 
Severe CHF, aneurysm, , HTN, past smoker (1/2 
ppd), anemic IABP placed 4/25/6 in preparation for 
OHT. 
 
Good health until 12/2005 when an upper 
respiratory illness brought 
him to his primary care physician. He was 
diagnosed with pneumonia and 
treated with 
 Milrinone, Dobutamine; lasix; heparin 
CONTROL 55 Hispanic Male Donor NF Pulmonary hypertension, gout, heavy drinker since teenager (12 pack/bottle wine per day)  
Dopamine, Heparin, Fentanyl Insulin, 
Albumin, Narcan, Neo, Vasopressin, 
Solumedrol, NS, Regular Insulin, Ancef 
CONTROL 61 White Male Donor NF 
Found unresponsive by wife CPR initiated in field 
pulse returned after 1 min.  Total DT approx 10mins.  
Hx - Crohn's, chole w/ sepsis 01/2007, drain in R 
lateral chest for pleural effusion, but nothing 
draining, bowel resection 1999, tibia/fibula broken 1 
CVA Pentasa, avelox, flomax, dopamine, insulin 
CONTROL 51 White Female Donor NF smoker (1ppd x30years), mild HTN, obese, left knee surgery CVA 
Labetolol, Cardene, Hydralazine, 
DDAVP, Heparin, Lasix, Mannitol, 
Dopamine, Albumin 
CONTROL 35 White Female Donor NF 
Pt found unresponsive after 5-6 hours of 
unresponsiveness before EMS was called.  CT 
showed bilateral CVA/hypoxic ischemic 
encephalopathy.  Hx of MVA 4.5 yrs ago, brain 
injury, chronic stomach pain, fx pelvis, arm, cranium, 
antidepressants, smoker 1ppd X 
CVA s/p OD 
Dopamine, levophed, insulin, nipride, 
ancef, solumedrol, narcan, CaCl, 








Race Gender Type heart Patient history Cause of death Meds (short list) 
CONTROL 56 White Female Donor NF 
Hx of Moyamoya disease w/ 2 prior CVA 1988, and 
1990.  Pt found down at home intubated in the field, 
no documented down time.  CT showed large ICH.  
Hx of HTN, smoked 1 ppd X10 yrs quit 7 yrs ago, 2-
4 beers/week, marijuana and acid weekly X 6 yrs 
quit 18 
CVA 
Lipitor, Dopamine, DDAVP, coumadin, 
ASA, thyroid meds, BP meds until 2 
mos ago, Albuterol, 
CASE 63 White Male CAD/ISCH 
LV dilatation, negative for ischemia on stress test 
11/06, atrial fibrillation, biventricular ICD 4/2002 with 
optimization in 01/2007, hyperlipidemia, chronic 
anticoagulation due to his underlying atrial 
fibrillation, vasectomy, gout, HTN and corneal tran 
 
Lisinopril 5 mg daily, digoxin 0.125 mg 
daily, Coumadin 2.5 mg four days a 
week, 1.25 three days a week; Coreg 
12.5 mg b.i.d., Lasix 40 mg a day, 
aspirin 81 mg a day, Zocor 40 mg a 
day, allopurinol 300 mg a day, 
spironolactone 12.5 mg a day. 
CONTROL 53 White Male Donor NF 
Pt seized in church EMS called by bystander and 
arrived with CPR in progress compressions only.  Pt 
was in sinus tachycardia in ED and given Epi and 
Atropine to stabilize.  CT showed SAH.  Hx of 
untreated HTN. 
CVA 
Epi (1mcg X2), Atropine (1mcgX2), 
Nipride, KCl, vasopressin, alprostadil, 
solumedrol, narcan, ancef 
CONTROL 69 Hispanic Male Donor NF 
Pt went to bed where wife found him w/ left sided 
weakness.  Pt transported to hospital and given tPA 
which led to bleed and BD.  Hx of splenectomy 
12/89, Foot surgery 1987, quit smoking 1989, quit 
EtOH 1979, flu shot fall 2006, laminectomy 7/13/07. 
CVA 
Pain meds for back pain.  KCl, Kphos, 
CaCl, Vasopressin, Labetolol, 
hydralazine, insulin, DDAVP, 
CASE 48 Middle Eastern Male CAD/ISCH 
Hx of ischemic cardiomyopathy, inferoposterior LV 
aneurysm and paroxysmal ventricular tachycardia 
s/p single chamber ICD implantation and s/p VT 
ablation 4/06, biopsy proven pulmonary sarcoidosis, 
DM 2, HTN, dyslipidemia, PTSD from previous ICD 
shocks 
 
Medications as of 8/27/7 (inpt):                      
1. Vasopressin drip at 0.04 
units/minute. 
2. Ativan and fentanyl drip for sedation. 
3. Insulin drip. 
4. Nexium 40 mg IV daily. 
5. Hydrocortisone 50 mg IV q.6 h. 
6. KCl 40 mEq via feeding tube b.i.d. 
7. 
CONTROL 40 White Male Donor NF 
Pt unhelmeted ATV accident ejected 20ft down a 
cliff.  Injuries - SAH, bilat SDH, bil 1 rub Fx, R 2nd 
rib Fx, grade II spleen lan, duodenal hematoma.  Pt 
developed PNA 10/10/07 given vancomycin.  PMHx 
- asthma as a child no Rx, allergies - bananas, 
pecans 







Race Gender Type heart Patient history Cause of death Meds (short list) 
CONTROL 60 White Male Donor NF SIGSW 12/18/2007.  Hx of 0.5 gallon EtOH/day for 1+ year, smoker 1ppd x 1yr, HTN, chronic back pain Self-inflicted GSW Dopamine, levophed, vasopressin, 
CONTROL 46 White Male Donor NF 
Pt admitted w/ aspiration following feeding tube 
change, Dx of bilat infilration secondary to aspiration 
pneumonia..  Hx of brain resection x5 for benign 
atypical meningioma, Gamma knife tx 9/94, 9/96, 
2/01, 1/07.  Hx of inhalation and puncture exposure t 
CVA T4, dopamine, neosynephrine, vasopressin, levophed, 
CASE 62 White Male CAD/ISCH 
1st MI in late 80's followed by severe MI in 1995. 
CABG 1997. NYHA II until 8/08. Biventricular 
pacemaker and defibrillator placed in 07/2008. 
Chronic renal insufficiency, Pulmonary hypertension, 
PVD, Hypothyroidism,  Obstructive sleep apnea, 
Gout, Htn. 
 
Medications as of 11/24/8:   Coumadin 
5.5 mg daily. Carvedilol 25 mg twice a 
day, digoxin 0.125 mg 
daily, aspirin 81 mg daily, Lasix 40 mg 
twice a day, lisinopril 5 mg 
daily, magnesium oxide 40 mg daily, 
niacin 1000 mg daily, isosorbide 
mononitrate 60 mg 
CASE 49 White Male CAD/ISCH 
2007 Cardiac cath and several stents placed. 
Abdominal surgery for diverticulitis w/ hospital 
course (several months) complicated by atrial 
fibrillation,  ARDS, and pnuemonia.  He later 
received an bi-v AICD for primary prevention against 
sudden cardiac d 
 
12/31/8 as Inpt:                                              
Digoxin 62.5 mcg p.o. Tuesday, 
Wednesday, Friday, Sunday, 
eplerenone 25 mg 
p.o. b.i.d., Gabapentin 300 mg q.a.m., 
600 mg at noon and 600 mg at p.m.. 
Multivitamin 1 tablet p.o. daily, vitamin 
C 
CASE 35 White Male CAD/ISCH 
1. Gout 2. Hyperlipidemia 3. ITP related to niacin 4. 
Ventricular tachycardia 5. Ischemic Cardiomyopathy 
6. Received a single chamber ICD in 2002. 6. Atrial 
fib. 7. PVD 
Died in OR following 
OHT of hemorrhagic 
shock 
Coreg 3.125mg 1 tablet bid,  Digoxin 
0.0625 mg daily, Demadex 20mg bid, 
Spironolactone 50mg in a.m. and 25mg 
in p.m., Zocor 40mg 1 tablet daily, 
Allopurinol 100mg 1 tablet daily, Asprin 
325mg 0.5 tablet daily,Levothyroxine 
Sodium 50mcg/day, Coumadin 5mg 
CASE 58 White Male CAD/ISCH 
Taken 5-21-09 Pre Tx: 1. Ischemic Cardiomyopathy 
with advance heart failure status post a HeartMate II 
LVAD as bridge to transplant therapy placed 
4/22/09. He also has a Paracor device placed 
7/2006. 2. CAD which is non-revascularizable at this 
point. 3. 
 
Taken 5-21-09 Pre Tx: 1. Coumadin 
7.5 mg M, W, F evenings as well s 5mg 
the other 4 nights 2. Aspirin 162mg 
daily 3. Lasix 40mg in morn & 20mg 
evening 4. Spironolactone 25mg daily 
5. KCl 20mEq daily 6. Pravochol 20 mg 







Race Gender Type heart Patient history Cause of death Meds (short list) 
CASE 51 White Male CAD/ISCH 
PAST MEDICAL HISTORY: 
Coronary artery disease with 3 anterior wall 
myocardial infarctions that 
led to a progressive decline in his ejection fraction 
from 45 percent in 
2005 to a severe decrease in the ejection fraction by 
02/2008 when he had cardiogenic s 
 
Include coumadin at 3 mg alternating 
with 2 mg every other day, aspirin 81 
mg every day, Inspra 50 mg in the 
morning, 25 mg in the evening, Toprol-
XL 
25 mg every day, Lasix 60 mg twice 
per day with an extra dose taken every 
so often, digoxin 0.125 mg ever 
CASE 59 White Male CAD/ISCH 
PAST MEDICAL HISTORY: 
1. Congestive heart failure. The patient was initially 
diagnosed in 11/2003 with this diagnosis. His 
cardiac catheterization and 
myocardial perfusion imaging results are 
summarized above. He had an 
echocardiogram originally performed 
 
CURRENT MEDICATIONS: 
1. Lasix 70 mg in the evening, 10 mg in 
the morning. The patient does 
adjust these doses based off of his 
ankle edema. 
2. Potassium chloride 30 mg p.o. daily. 
3. Metformin 1,000 mg p.o. b.i.d. 
4. Ramipril 5 mg daily. 
5. Spironolactone 
CASE 65 White Male Ischemic/CAD 
Ischemic cardiomyopathy, CABG '81; rotational 
artherectomy '87; VT '98 with ICD with DDD placed;, 
DM, hypothyroidism, sleep apnea; amiodarone lung 
toxicity; hyperlipidemia 
N/A 
As of 4/8/3:  Prinivil 10 mg q. a.m., 50 
mg q. 
p.m.;  Lasix 40 mg b.i.d., Synthroid 112 
mcg q.d.; Imdur 60 mg 
q.d.; Zantac 150 mg b.i.d.; Digoxin 
0.125 mg q.d.; Lipitor 15 mg 
q.d.; spironolactone 25 mg q.d.; 
Coumadin 5 mg 3 times a week, 
2.5 mg 4 times a week; baby aspirin 81 
mg q.d.;  magnesium 
gluconate 1 gram q.d.; potassium 275 
mcg q.d.; Glucotrol 5 mgb.i.d.; Actos 30 
mg q. p.m.; amiodarone 400 mg q.d.; 
metoprolol 







Race Gender Type heart Patient history Cause of death Meds (short list) 
CASE 62 White Male Ischemic/CAD 
Severe isch. CM,  AICD and bivent pacer 2/03, 
NYHA class 4, OSA on CPAP, MI '74 and '86; 
CABG '74, vent arrythmias, high cholest., 
hyperthyroid. 
N/A 
As of 6/3/3:  Lasix 20 mg q.d., Coreg 
6.25 mg b.i.d., Zestril 40 mg q.d., 
spironolactone 12.5 mg b.i.d., 
amiodarone 200 mg q.d., Topazone 2.5 
mgq.d., lovastatin 40 mg q.h.s., 
Coumadin 5 mg q.d., Digoxin 0.125 mg 
q.d.,aspirin baby 81 mg q.d., vitamin C 
500 mg once a day, vitamin A 1000 mg 
a 
day, vitamin D 1000 mg a day, CoQ10 
100 mg q.d., garlic 300 mg 
b.i.d.,selenium 1 tablet a day, Isordil 45 
mg t.i.d., folic acid 1 tablet a 
day,hydralazine 75 mg t.i.d., calcium 
600 mg q.d., multivitamin 1 tablet a 
day, Omega-3 fish oil 1 tablet a day, 
turmeric tablets 1 tablet b.i.d.,vinegar 
tablets 2 tablets b.i.d. 
CASE 56 White Female Ischemic/CAD 
sarco iliac dislocation 2 years ago, family history of 
heart disease,  
type 2 diabetes mellitus, history of cardiac arrest for 
which she 
has an AICD in place (2003), chronic atrial 
fibrillation, sleep apnea syndrome for which she is 
on BiPAP therapy, hyperlipidemia, chronic 
anticoagulationbecause of her atrial fibrillation and 
low ejection fraction, and underlying left bundle 
branch block for which she also has a biventricular 
pacemaker in place. 
Participated in EMPOWER Trial. 
N/A 
Meds as of 9/28/4:  Coumadin 4 mg 
twice a week, 2 mg five times a week, 
Aldactone 50 mg b.i.d., amiodarone 
200 mg q. day, Demadex 20 mg 
q.a.m., 10 mg q.p.m., fish oil 1 gram q. 
day, Imdur 30 mg q. day, 
Pravachol 40 mg q. day, Zaroxolyn 
1.25 mg q.a.m., baby aspirin 81 mg q. 
day, hydralazine 25 mg q.i.d., Capoten 
25 mg t.i.d., Plavix 75 mg q. day, 
Digoxin 0.0625 mg six times a week, 
multivitamin q. day, folic acid 1 one 
tablet a day, Ambien 5 mg q.h.s., 
potassium 100 mEq q.a.m., 60 mEq 
q.p.m., 
EMPOWER study drug. 
CASE 60 White Female Ischemic/CAD 
MI 1986; CAD; CABG x4 9/99; Angioplasty to Cx 
9/02 CRT-D pacemaker 9/27/4; dyslipidemia; 
diabetes; cholelithiasis; splenic infarct; family hist of 
HD; PHTN 
N/A None listed 
CASE 58 White Male Ischemic/CAD 
ischemic cardiomyopathy, coronary bypass and 
MVR 12/2004;  defibrillator, HTN, type 2 diabetes; 
MVR 1/2005 ;  hyperlipidemia; BiV/ICD placed 
1/2005. 
AWMI 8/2000 and at that time he had stents placed 
in his 




As of1. Pacerone 200 mg p.o. daily. 
2. Cozaar 50 mg p.o. daily. 
3. Aldactone 25 mg p.o. b.i.d. 
4. Lasix 60 mg in the morning, 40 mg 
at night. 
5. Klor-Con 20 mEq p.o. daily. 
6. Coumadin 2 mg alternating with 3 
mg. 







Race Gender Type heart Patient history Cause of death Meds (short list) 
8. Zocor 40 mg p.o. daily. 
9. Nexium 40 mg p.o. daily. 
10. Nitroglycerin patch 0.2 mg per 
hour. 
11. Digoxin 0.125 mg alternating with 
0.0625 mg. 
CASE 61 White Male Ischemic/CAD 
Dilated cardiomyopathy, ischemic . History of 
several vessel bypass surgery with SVG to the RCA 
in 2002. At that time he sustained a significant right 
ventricle infarct. Right ventricular 
function was preserved. Subsequently he underwent 
placement to his RCA in 01/2006.  Chronic atrial 
fibrillation.   ICD,  Ventricular arrhythmia,  
Hyperlipidemia, Hypothyroidism, Obstructive sleep 
apnea, Diverting colostomy placed after colonic 
perforation, Chronic anxiety due to right heart 
failure, Chronic anticoagulation for his atrial 
fibrillation, Osteoporosis, Amiodarone lung toxicity, 
tricuspid valve ring placement. In 05/2001, 
had an annuloplasty with placement of an epicardial 
lead as the 
defibrillator lead led to the severe tricuspid 
regurgitation. Cardiac cirrhosis. 
N/A 
Medications as of 11/30/7:                          
1. Milrinone IV infusion at 0.375 mg per 
hour. 
2. Heparin IV infusion. 
3. Furosemide 80 mg IV t.i.d. 
4. Synthroid 50 mcg p.o. daily. 
5. Aspirin 81 mg p.o. daily. 
6. Digoxin 125 mcg p.o. daily. 
7. Docusate 100 mg p.o. b.i.d. 
8. Senna 1 tab p.o. b.i.d. 
9. Nexium 40 mg p.o. daily. 
10. Folate 1 mg p.o. daily. 
11. Amiloride 10 mg p.o. daily. 
12. Darbepoetin 12.5 mg subcutaneous 
weekly. 
13. Calcium carbonate 1 tab p.o. b.i.d. 
CONTROL 45 White Female Non-Failing 
High Risk Donor - incarcerated for 151 days for 
DUI/Grand theft auto, Blood alcohol level 224 when 
admitted, EMS found pt with fixed/dilated pupils and 
agonal respirations, intubated and transported to 
hospital, sever CHI, received 2 units PRBC in ED. 
Htn for past 5 years (compliant with meds), 
depression, ETOH, vicodin and valium abuse. 
Hemorrhoid repair 2008. Meds: bp meds(unknown), 
MVI, vicodin, valium, amitryptyline. Smoked 1ppd x 
30years, daily ETOH/vicodin/valium, cocaine, 
marijuana, and smoked meth 1-2 times last use 
several years ago. CT scan showed large left 




Dopamine 12.00 mcg/kg/min, Ancef 
1.00 gm, T4 25.00 ml/hr, hydralazine 








Race Gender Type heart Patient history Cause of death Meds (short list) 
CONTROL 65 Hispanic Male Non-Failing 
Arrival at ED pt's GCS=3, was intubated. Hx of long-
term coumadin use, admission INR=5.5. CT showed 
large intracerebral hemorrhage w/ herniation on heat 
CT. Htn for 12yrs (compliant w/ meds), Diabetes 
20+ yrs (insulin injections nightly), high cholesterol. 
Hospitalized 8 yrs ago for DVT in foot. Quit smoking 
3 yrs ago. Daily meds:Glipizide, Coumadin, Zocor, 
Cozaar, Aspirin, Metformin, Lantus, Lasix, Lisinopril. 
Cerebrovascular/Stroke 
Insulin 1.00 units/hr, Nicardipine 5.00 
mg/hr, T4 10.00mcg/hr, Dextrose 1.00 
amp, Insulin 20.00 units, K+ 10.00mEq, 
Solumedrol 2.00 Gm. Daily 
meds:Glipizide, Coumadin, Zocor, 
Cozaar, Aspirin, Metformin, Lantus, 
Lasix, Lisinopril. 
CASE 63 Hispanic Female Ischemic/CAD 
Breast Carcinoma (2001) (underwent chemo), 
Diabetes Mellitus, Hypothyroidism, Atrial Fibrilation, 
Coronary Artery Disease, s/p MI underwent stenting 
in 2003, Chronic Renal Failure, Scleroderma, 
Hyperlipidemia, Congestive heart failure with 
ischemic etiology, PVD, GAVE syndrome 
N/A 
MEDICATIONS: 
1. Dobutamine drip. 
2. Milrinone drip. 
3. Lasix drip. 
4. Heparin drip. 
5. Hydralazine 25 mg p.o. t.i.d. 
6. Iron sulfate 325 mg daily. 
7. Isosorbide dinitrate 10 mg p.o. t.i.d. 
8. Docusate 100 mg p.o. b.i.d. 
9. Nexium 40 mg p.o. daily. 
10. Levothyroxine 112 mcg p.o. daily. 
11. Nephro-Vite 1 tablet p.o. daily. 
12. EPO 10,000 units on Tuesday, 
Thursday, Saturday. 
13. Cefazolin 2 g IV q.8h. 
14. Ambien p.r.n. 
15. Tylenol p.r.n. 
16. Zofran p.r.n. 
CONTROL 20 White Male Non-Failing 
1) Broken right wrist 2007 
(2) Occassionally smoked cigarettes and Cigars 
once and a while for about 3 years.  
(3) Drank 4 times a week for 6 years (beer & 
Captain Morgan w/Pepsi) 
(4) Marijuana (few times a week) 2 yrs 
(5) Ecstacy (during concerts) 
(6) Acid (5 times in one year) 
(7) Cough from smoking predominately when laying 
down (6 months) 
(8) Arthitis from skatting shoulders, knees, hips, and 
wrists 
Head Trauma (Blunt 
Injury) 
After Brain Death:                                           
(1) Levophed (15.00 mcg/kg/min)                  
(2) Vasopressin (6.00 units/hr)                         
(3) T4                                                              







Race Gender Type heart Patient history Cause of death Meds (short list) 
CONTROL 38 White Male Non-Failing 
(1) Apendecotomy @ age 21 Swedish Hospital 
(2) Skin graft on gums from chewing/herditary 
(3) Smoked 1 pack a day for 10 years 
(4) Chew tabacco several times 6 months ago 
(5) Couple of drinks for 10yrs (Beer) 
(6) Broken wrist @ age 14 
Head Trauma (gunshot 
wound) 
After Brain Death:  (1) Ampicillin (3.00 
Gm)                                   (2) 
Hydralazine (10.00 mg) (3) Labetalol 
(10.00 mg)                                  (4) 
Levophed (20.00 mcg/min)                        
(5) Neosynephrine (5.00 mcg/min)                  
(6) T4 (10.00 mcg/hr)                                      
(7) Vasopressin (.04 units/min) 
CONTROL 46 Hispanic Male Non-Failing  
Respiratory/Cardiac 
Arrest s/p thyroidectomy 
Thyroid Medication, Medication Post 
Mordom (see donor alliance patient 
file) 
CONTROL 56 White Female Non-Failing 
1) Thyroid Condition 
2) Pneumonia 26 yrs ago 
3) Fungal infection on toes-recurring 
4) 2 C-sections (1984 & 1986) 
5) Exposed to H1N1 took tamaflu last 3 wks, no 
symptoms 
6) Allergies (Cottonwood, and possible sulfate) 
7) High blood pressure 
8) Poor circulation in the legs 




1) B complex                                                   
2) Fluoxetinc 20mg                                          
3) Hydroohlorothiazide 25mg                         
4) Lerothy Maxine .075 mg 
5) Acid reflux drugs                                         
(See patient file for post-mortem) 
CONTROL 58 White Female Non-Failing Stroke 12-29-2009, quit smoking 5 years ago, H1N1 9/2009, osteoarthritus Cerebrovascular/Stroke Chole Meds, Asprin, Sleep-Aid 
CASE 60 White Male Ischemic/CAD 
2. Left ventricular thrombus. 
3. Gout. 
4. Coronary artery disease. 
5. Hypertension. 
6. Hyperlipidemia. 
7. ICD placement secondary to refractory ventricular 
fibrillation/ventricular tachycardia. 
8. Malnutrition. 








1. Lasix 40 mg IV b.i.d. 
2. Ergocalciferol 50,000 international 
units p.o. q. week. 
3. Digoxin 62.5 mcg p.o. daily. 
4. Eplerenone 25 mg p.o. daily. 
5. Zofran 4 mg p.o. daily. 
6. Ranitidine 150 mg p.o. b.i.d. 
7. Amiodarone 200 mg p.o. b.i.d. 
8. Colace 100 mg p.o. b.i.d. 
9. Senna 2 tabs p.o. b.i.d. 
10. Potassium chloride 20 mg p.o. 
b.i.d. 







Race Gender Type heart Patient history Cause of death Meds (short list) 
2. Bi-V ICD placement. 12. Mexiletine 200 mg p.o. b.i.d. 
13. Captopril 3.125 mg p.o. t.i.d. 
14. Atorvastatin 20 mg p.o. at bedtime. 
CONTROL 50 White Female Non-Failing Possible thyroid issue, Mitral regurgitation discovered at time of donation Cerebrovascular/Stroke 
Hyperthyroid meds, estrogen, birth 
control 
CASE 65 White Male Ischemic/CAD 
Diagnosed in 1997 
Coronary artery disease status post  three-vessel 
bypass 
grafting in 11/2004 with patent grafts. 
Hx of afib/flutter 
Dyslipidemia 
Hemochromatosis gene testing revealed the 
presence of one allele of the C-282-Y 
hemochromatosis gene.  He is thought to be a 
heterozygote for hemochromatosis. 
N/A 
As of 10/20/10: Coumadin daily, aspirin 
81 mg daily, Coreg 25 mg b.i.d., 
Cozaar 25 mg 
b.i.d., Inspra 50 mg daily, Lasix 20 mg 
daily plus 20 p.r.n., potassium 
chloride 20 mEq b.i.d.+ 20 extra p.r.n., 
Crestor 5 mg every other day, 
Zetia 10 mg daily, multivitamin daily, 
Xanax 1.5 mg at bedtime, Colace two 
to three tablets at bedtime, 
supplemental oxygen nightly, Bactrim 
double-strength b.i.d. 
CONTROL 60 White Female Non-Failing 
Med/ Soc found appendectomy in teenage years, 
gall bladder removed 1979, 1 glass of wine per day, 
and was vaccinated of Hepatitis B due to work in the 
medical field, broken finger 2001, heart murmur 
since birth 
Cerebrovascular/Stroke 
Estrogen regime, daily vitamin, acute: 
dopamine 4 MCG/KG/MIN, 
neosynephrine 2 MCG/KG/MIN, Solu-
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CASE 50 White Male Ischemic/CAD 
LVAD 3/4/11 
AWMI ~2/14/2011 complicated by cardiogenic 
shock; IABP placed VT after MI 
GERD 




As of 4/7/11: Coumadin daily, 
carvedilol 3.125 mg b.i.d., docusate 
100 mg daily, 
Prilosec daily, citalopram 20 mg daily, 
hydralazine 50 mg t.i.d., 
potassium phosphate t.i.d., amiodarone 
400 mg daily, mexiletine 150 mg 
t.i.d., lisinopril 40 mg daily, Lasix was 
discontinued, aspirin 81 mg 
daily, spironolactone 12.5 mg b.i.d., 
polyethylene glycol p.r.n., vitamin 
D 50,000 units weekly, folic acid 1 mg 
daily, Roxicodone p.r.n., Vicodin 
5/500 q.6 hours p.r.n., and Ambien 5 
mg at bedtime p.r.n 
CONTROL 43 White Male Non-Failing 
High cholesterol, DM II (Diabetes mellitus type 2), 
(both controlled with meds unknow name and dose). 
Phych issues but not listed (on meds for this too) 
Hanging, Suicide Meds for high cholesterol, DM II, & phych meds 
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